FDMT
4D Molecular TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive readouts and/or a major partnership would validate the capsid platform, accelerate licensing/revenue potential and prompt multiple expansion.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -6.0.
What can break
Negative trial results, manufacturing or regulatory setbacks, or dilutive financings would materially compress valuation for this small‑cap biotech.
Momentum
89
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.98 · Bull $2.97 · Bear $0.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-24 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $27.63
Why
Momentum89 · Δ7d -6.0
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendSoftening
Δ7d
-6.0
Δ21d
+4.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 89.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$594.64M
Beta
3.00
Shares Out
52.28M
P/E (TTM) · Derived
-4.7
P/S (TTM)
3475.72
P/FCF (TTM) · Derived
-5.40
Rev YoY
+21664.3%
EPS YoY
+17.4%
Gross Margin
+91.0%
Op Margin
-191982.5%
Net Debt
-$381.24M
Current Ratio
9.34
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology